{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T02:26:26Z","timestamp":1772331986053,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100018556","name":"Science and Technology Program of Suzhou","doi-asserted-by":"publisher","award":["SKJY2021025"],"award-info":[{"award-number":["SKJY2021025"]}],"id":[{"id":"10.13039\/501100018556","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalradiologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Radiology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.crad.2023.07.011","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T06:05:37Z","timestamp":1691042737000},"page":"e839-e846","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Discriminating minimal residual disease status in multiple myeloma based on MRI: utility of radiomics and comparison of machine-learning methods"],"prefix":"10.1016","volume":"78","author":[{"given":"X.","family":"Xiong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Q.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.crad.2023.07.011_bib1","first-page":"58","article-title":"Haematology: multiple myeloma","volume":"19","author":"Firth","year":"2019","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.crad.2023.07.011_bib2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/14656566.2018.1441287","article-title":"Proteasome inhibitors for the treatment of multiple myeloma","volume":"19","author":"Scalzulli","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.crad.2023.07.011_bib3","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.crad.2023.07.011_bib4","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.crad.2023.07.011_bib5","doi-asserted-by":"crossref","first-page":"7583","DOI":"10.2147\/OTT.S122241","article-title":"Non-secretory multiple myeloma: from biology to clinical management","volume":"9","author":"Dupuis","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.crad.2023.07.011_bib6","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.crad.2023.07.011_bib7","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood-2010-09-307645","article-title":"Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients","volume":"117","author":"Gay","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.crad.2023.07.011_bib8","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.crad.2023.07.011_bib9","first-page":"1365","article-title":"Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry","volume":"90","author":"Sarasquete","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.crad.2023.07.011_bib10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1083-8791(00)70006-1","article-title":"Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma","volume":"6","author":"Ladetto","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.crad.2023.07.011_bib11","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1182\/blood.V99.5.1853","article-title":"Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome","volume":"99","author":"San","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.crad.2023.07.011_bib12","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of (18)F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.crad.2023.07.011_bib13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/02841859809172146","article-title":"MR imaging of multiple myeloma patients with bone-marrow transplants","volume":"39","author":"Agren","year":"1998","journal-title":"Acta Radiol"},{"key":"10.1016\/j.crad.2023.07.011_bib14","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3390\/cancers12030761","article-title":"Extended texture analysis of non-enhanced whole-body mri image data for response assessment in multiple myeloma patients undergoing systemic therapy","volume":"12","author":"Ekert","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.crad.2023.07.011_bib15","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/jmri.27637","article-title":"Prediction of high-risk cytogenetic status in multiple myeloma based on magnetic resonance imaging: utility of radiomics and comparison of machine learning methods","volume":"54","author":"Liu","year":"2021","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.crad.2023.07.011_bib16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/cyto.b.20512","article-title":"Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders","volume":"78","author":"Paiva","year":"2010","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.crad.2023.07.011_bib17","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1002\/mp.13678","article-title":"Machine and deep learning methods for radiomics","volume":"47","author":"Avanzo","year":"2020","journal-title":"Med Phys"},{"key":"10.1016\/j.crad.2023.07.011_bib18","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.acra.2017.12.008","article-title":"Discriminating depth of response to therapy in multiple myeloma using whole-body diffusion-weighted MRI with apparent diffusion coefficient: preliminary results from a single-center study","volume":"25","author":"Wu","year":"2018","journal-title":"Acad Radiol"},{"key":"10.1016\/j.crad.2023.07.011_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2019.108695","article-title":"Whole-body diffusion-weighted MRI for evaluation of response in multiple myeloma patients following bortezomib-based therapy: a large single-center cohort study","volume":"120","author":"Zhang","year":"2019","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.crad.2023.07.011_bib20","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","article-title":"Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study","volume":"31","author":"Rawstron","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.crad.2023.07.011_bib21","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1078-0432.CCR-21-3430","article-title":"A machine learning model based on tumor and immune biomarkers to predict undetectable MRD and survival outcomes in multiple myeloma","volume":"28","author":"Guerrero","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.crad.2023.07.011_bib22","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1148\/radiol.14131944","article-title":"Adult advanced chronic lymphocytic leukemia: computational analysis of whole-body CT documents a bone structure alteration","volume":"271","author":"Fiz","year":"2014","journal-title":"Radiology"},{"key":"10.1016\/j.crad.2023.07.011_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2020.109214","article-title":"Mid-term response assessment in multiple myeloma using a texture analysis approach on dual energy-CT-derived bone marrow images\u2014a proof of principle study","volume":"131","author":"Reinert","year":"2020","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.crad.2023.07.011_bib24","first-page":"14","article-title":"A novel SVM based CSSFFS feature selection algorithm for detecting breast cancer","volume":"31","author":"Aruna","year":"2011","journal-title":"Int J Comput Appl"},{"key":"10.1016\/j.crad.2023.07.011_bib25","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jclinepi.2015.02.010","article-title":"The precision\u2013recall curve overcame the optimism of the receiver operating characteristic curve in rare diseases","volume":"68","author":"Ozenne","year":"2015","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.crad.2023.07.011_bib26","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1007\/s00330-020-07320-8","article-title":"Role of computed tomography texture analysis using dual-energy-based bone marrow imaging for multiple myeloma characterization: comparison with histology and established serologic parameters","volume":"31","author":"Reinert","year":"2021","journal-title":"Eur Radiol"}],"container-title":["Clinical Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009926023003185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009926023003185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T20:13:37Z","timestamp":1762114417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009926023003185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0009926023003185"],"URL":"https:\/\/doi.org\/10.1016\/j.crad.2023.07.011","relation":{},"ISSN":["0009-9260"],"issn-type":[{"value":"0009-9260","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discriminating minimal residual disease status in multiple myeloma based on MRI: utility of radiomics and comparison of machine-learning methods","name":"articletitle","label":"Article Title"},{"value":"Clinical Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.crad.2023.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}]}}